Revolution Medicines Reports Daraxonrasib Survival Benefit Across PDAC Subgroups
Exploratory Phase 3 RASolute 302 subgroup data showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (HR 0.40) in previously treated metastatic PDAC, consistent with the primary analysis.